{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:02:54Z","timestamp":1791468174101,"version":"4.3.4"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jcim-2026-0281_abs_001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\u2018Gentisic acid is a phenolic compound that contains anti-inflammatory and antioxidant characteristics and could help prevent oxidative stress and damage to the liver caused by MASLD. Gentisic acid\u2019s medicinal potential is poorly investigated and not widely studied.\u2019<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2026-0281_abs_002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\u2018To evaluate the hepatoprotective effect of gentisic acid in rats fed high fat and high fructose (HFHFr) diet, physical, biochemical and histopathological parameters were studied in experimental rats.\u2019<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2026-0281_abs_003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\u2018Male Wistar rats were randomly allocated into five groups: Normal Control (NC), Disease Control (DC; HFHFr diet), Standard (pioglitazone, 3\u202fmg\/kg, p.o.), GA I (40\u202fmg\/kg, p.o.), and GA II (80\u202fmg\/kg, p.o.). Treatments were administered during the final 14\u00a0days of the study. At the end, blood samples were collected for biochemical analysis, while visceral fat and liver tissues were excised for histopathological evaluation.\u2019<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2026-0281_abs_004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GA significantly improved metabolic and liver abnormalities in HFHFr diet-induced MASLD rats. It reduced weight gain, liver weight, visceral fat, blood glucose, lipidic markers, liver enzymes and inflammatory markers; increasing the HDL levels. Histopathological study also revealed decreased steatosis, inflammation, lipid, and hepatocellular damage and\u00a0restored the normal liver architecture demonstrating a dose-dependent response. Results confirm that GA has hepatoprotective and antihyperlipidemic effects in the treatment of MASLD, which are supported by scientific evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2026-0281_abs_005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GA II at dose of 80\u202fmg\/kg revealed strong hepatoprotective action against HFHFr diet induced MASLD in rats by improving biochemical and histopathological parameters. The results show some good preclinical support for use in the treatment of MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jcim-2026-0281","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:29:51Z","timestamp":1791466191000},"source":"Crossref","is-referenced-by-count":0,"title":["Gentisic acid attenuates high fat and high fructose diet-induced metabolic dysfunction-associated steatotic liver disease through modulation of metabolic and hepatic alterations in Wistar rats"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9329-5212","authenticated-orcid":false,"given":"Deepti Dinesh","family":"Bandawane","sequence":"first","affiliation":[{"name":"Department of Pharmacology , Progressive Education Society\u2019s Modern College of Pharmacy , Pune , Maharashtra , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8278-211X","authenticated-orcid":false,"given":"Sakshi Sachin","family":"Katke","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Progressive Education Society\u2019s Modern College of Pharmacy , Pune , Maharashtra , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8911-6507","authenticated-orcid":false,"given":"Ketaki Hemant","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Progressive Education Society\u2019s Modern College of Pharmacy , Pune , Maharashtra , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026100813294635505_j_jcim-2026-0281_ref_001","doi-asserted-by":"crossref","unstructured":"Miller, DM, McCauley, KF, Dunham-Snary, KJ. Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances. Endocrinol Diabetes Metab 2025;8:e70132. https:\/\/doi.org\/10.1002\/edm2.70132.","DOI":"10.1002\/edm2.70132"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_002","doi-asserted-by":"crossref","unstructured":"Younossi, ZM, Golabi, P, Paik, JM, Henry, A, Van Dongen, C, Henry, L, et al.. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77:1335\u201347. https:\/\/doi.org\/10.1097\/hep.0000000000000004.","DOI":"10.1097\/HEP.0000000000000004"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_003","doi-asserted-by":"crossref","unstructured":"Paik, JM, Henry, L, Younossi, Y, Ong, J, Alqahtani, S, Younossi, ZM, et al.. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 2023;7:e0251. https:\/\/doi.org\/10.1097\/hc9.0000000000000251.","DOI":"10.1097\/HC9.0000000000000251"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_004","doi-asserted-by":"crossref","unstructured":"Wang, D, Miao, J, Zhang, L, Zhang, L. Research advances in the diagnosis and treatment of MASLD\/MASH. Ann Med 2025;57:2445780. https:\/\/doi.org\/10.1080\/07853890.2024.2445780.","DOI":"10.1080\/07853890.2024.2445780"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_005","doi-asserted-by":"crossref","unstructured":"Phoolchund, AG, Khakoo, SI. MASLD and the development of HCC: pathogenesis and therapeutic challenges. Cancers (Basel) 2024;16:259. https:\/\/doi.org\/10.3390\/cancers16020259.","DOI":"10.3390\/cancers16020259"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_006","doi-asserted-by":"crossref","unstructured":"Scoditti, E, Sabatini, S, Carli, F, Gastaldelli, A. Hepatic glucose metabolism in the steatotic liver. Nat Rev Gastroenterol Hepatol 2024;21:319\u201334. https:\/\/doi.org\/10.1038\/s41575-023-00888-8.","DOI":"10.1038\/s41575-023-00888-8"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_007","doi-asserted-by":"crossref","unstructured":"Targher, G, Byrne, CD, Tilg, H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024;73:691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","DOI":"10.1136\/gutjnl-2023-330595"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_008","doi-asserted-by":"crossref","unstructured":"Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L, Torres-Gonzalez, A, Gra-Oramas, B, Gonzalez-Fabian, L, et al.. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367\u201378. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_009","doi-asserted-by":"crossref","unstructured":"Hashida, R, Kawaguchi, T, Bekki, M, Omoto, M, Matsuse, H, Nago, T, et al.. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J\u00a0Hepatol 2017;66:142\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.023.","DOI":"10.1016\/j.jhep.2016.08.023"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_010","doi-asserted-by":"crossref","unstructured":"Koutoukidis, DA, Koshiaris, C, Henry, JA, Noreik, M, Morris, E, Manoharan, I, et al.. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2021;115:154455. https:\/\/doi.org\/10.1016\/j.metabol.2020.154455.","DOI":"10.1016\/j.metabol.2020.154455"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_011","doi-asserted-by":"crossref","unstructured":"Abedi, F, Razavi, BM, Hosseinzadeh, H. A review on gentisic acid as a plant-derived phenolic acid and metabolite of aspirin: comprehensive pharmacology, toxicology, and some pharmaceutical aspects. Phytother Res 2020;34:729\u201341. https:\/\/doi.org\/10.1002\/ptr.6573.","DOI":"10.1002\/ptr.6573"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_012","doi-asserted-by":"crossref","unstructured":"Joshi, R, Gangabhagirathi, R, Venu, S, Adhikari, S, Mukherjee, T. Antioxidant activity and free radical scavenging reactions of gentisic acid: in\u00a0vitro and pulse radiolysis studies. Free Radic Res 2012;46:11\u201320. https:\/\/doi.org\/10.3109\/10715762.2011.633518.","DOI":"10.3109\/10715762.2011.633518"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_013","doi-asserted-by":"crossref","unstructured":"Li, Y, Yang, P, Ye, J, Xu, Q, Wu, J, Wang, Y, et al.. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis 2024;23:117. https:\/\/doi.org\/10.1186\/s12944-024-02108-x.","DOI":"10.1186\/s12944-024-02108-x"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_014","doi-asserted-by":"crossref","unstructured":"Ashidate, K, Kawamura, M, Mimura, D, Tohda, H, Miyazaki, S, Teramoto, T, et al.. Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma. Eur J Pharmacol 2005;513:173\u20139. https:\/\/doi.org\/10.1016\/j.ejphar.2005.03.012.","DOI":"10.1016\/j.ejphar.2005.03.012"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_015","doi-asserted-by":"crossref","unstructured":"Mardani-Ghahfarokhi, A, Farhoosh, R. Antioxidant activity and mechanism of inhibitory action of gentisic and \u03b1-resorcylic acids. Sci Rep 2020;10:19487. https:\/\/doi.org\/10.1038\/s41598-020-76620-2.","DOI":"10.1038\/s41598-020-76620-2"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_016","doi-asserted-by":"crossref","unstructured":"Razliqi, RN, Ahangarpour, A, Mard, SA, Khorsandi, L. Gentisic acid ameliorates type 2 diabetes induced by nicotinamide-streptozotocin in male mice by attenuating pancreatic oxidative stress and inflammation through modulation of Nrf2 and NF-\u03baB pathways. Life Sci 2023;325:121770. https:\/\/doi.org\/10.1016\/j.lfs.2023.121770.","DOI":"10.1016\/j.lfs.2023.121770"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_017","doi-asserted-by":"crossref","unstructured":"Mechchate, H, Es-Safi, I, Mohamed Al Kamaly, O, Bousta, D. Insight into gentisic acid antidiabetic potential using in\u00a0vitro and in\u00a0silico approaches. Molecules 2021;26:1932. https:\/\/doi.org\/10.3390\/molecules26071932.","DOI":"10.3390\/molecules26071932"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_018","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Berumen, CI, Ortiz-Avila, O, Vargas-Vargas, MA, del Rosario-Tamayo, BA, Guajardo-L\u00f3pez, C, Saavedra-Molina, A, et al.. The severity of rat liver injury by fructose and high fat depends on the degree of respiratory dysfunction and oxidative stress induced in mitochondria. Lipids Health Dis 2019;18:78. https:\/\/doi.org\/10.1186\/s12944-019-1024-5.","DOI":"10.1186\/s12944-019-1024-5"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_019","doi-asserted-by":"crossref","unstructured":"Chung, S, Kim, HJ, Choi, HK, Park, JH, Hwang, JT. Comparative study of the effects of diosmin and diosmetin on fat accumulation, dyslipidemia, and glucose intolerance in mice fed a high-fat high-sucrose diet. Food Sci Nutr 2020;8:5976\u201384. https:\/\/doi.org\/10.1002\/fsn3.1883.","DOI":"10.1002\/fsn3.1883"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_020","doi-asserted-by":"crossref","unstructured":"Yin, J, Xing, H, Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712\u201317. https:\/\/doi.org\/10.1016\/j.metabol.2008.01.013.","DOI":"10.1016\/j.metabol.2008.01.013"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_021","doi-asserted-by":"crossref","unstructured":"Madureira, AR, Martins, VV, Cardoso, JC, Torezani-Sales, S, Miranda, KD, Salgado, BS, et al.. High-fat diet induces MASLD and adipose tissue changes in obesity-resistant rats. Cell Physiol Biochem 2025;59:434\u201352. https:\/\/doi.org\/10.33594\/000000791.","DOI":"10.33594\/000000791"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_022","doi-asserted-by":"crossref","unstructured":"Sarkar, S, Ghosh, S, Biswas, M. Naringin ameliorates high-fat diet-induced hepatotoxicity and dyslipidemia in experimental rat model via modulation of antioxidant enzymes, AMPK and SREBP-1c signalling pathways. Toxicol Rep 2025;14:102062. https:\/\/doi.org\/10.1016\/j.toxrep.2025.102062.","DOI":"10.1016\/j.toxrep.2025.102062"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_023","doi-asserted-by":"crossref","unstructured":"Huang, DW, Chang, WC, Wu, JS, Shih, RW, Shen, SC. Gallic acid ameliorates hyperglycaemia and improves hepatic carbohydrate metabolism in rats fed a high-fructose diet. Nutr Res 2016;36:150\u201360. https:\/\/doi.org\/10.1016\/j.nutres.2015.10.001.","DOI":"10.1016\/j.nutres.2015.10.001"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_024","doi-asserted-by":"crossref","unstructured":"Mopuri, R, Kalyesubula, M, Rosov, A, Edery, N, Moallem, U, Dvir, H, et al.. Improved Folch method for liver-fat quantification. Front Vet Sci 2021;7:594853. https:\/\/doi.org\/10.3389\/fvets.2020.594853.","DOI":"10.3389\/fvets.2020.594853"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_025","doi-asserted-by":"crossref","unstructured":"Kang, MJ, Choi, W, Yoo, SH, Nam, SW, Shin, PG, Kim, KK, et al.. Modulation of inflammatory pathways and adipogenesis by the action of gentisic acid in RAW 264.7 and 3T3-L1 cell lines. J\u00a0Microbiol Biotechnol 2021;31:1079\u201388. https:\/\/doi.org\/10.4014\/jmb.2105.05004.","DOI":"10.4014\/jmb.2105.05004"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_026","doi-asserted-by":"crossref","unstructured":"Noei, RR, Ahangarpour, A, Mard, SA, Khorsandi, L. Gentisic acid protects against diabetic nephropathy in nicotinamide-streptozotocin administered male mice by attenuating oxidative stress and inflammation: the role of miR-200a\/Keap1\/Nrf2 pathway, renin-angiotensin system (RAS) and NF-\u03baB. Chem Biol Interact 2023;380:110507.","DOI":"10.1016\/j.cbi.2023.110507"},{"key":"2026100813294635505_j_jcim-2026-0281_ref_027","doi-asserted-by":"crossref","unstructured":"Pujari, RR, Bandawane, DD. Hepatoprotective activity of gentisic acid on 5 fluorouracil induced hepatotoxicity in Wistar rats. Turk J Pharm Sci 2021;18:332\u20138. https:\/\/doi.org\/10.4274\/tjps.galenos.2020.95870.","DOI":"10.4274\/tjps.galenos.2020.95870"}],"container-title":["Journal of Complementary and Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2026-0281\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2026-0281\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:29:55Z","timestamp":1791466195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2026-0281\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":27,"alternative-id":["10.1515\/jcim-2026-0281"],"URL":"https:\/\/doi.org\/10.1515\/jcim-2026-0281","relation":{},"ISSN":["2194-6329","1553-3840"],"issn-type":[{"value":"2194-6329","type":"print"},{"value":"1553-3840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}